← Back to Clinical Trials
Recruiting NCT07237295

NCT07237295 CommunityRx-Kidney Health

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07237295
Status Recruiting
Phase
Sponsor University of North Carolina, Chapel Hill
Condition Chronic Kidney Disease (Stages 1-4)
Study Type INTERVENTIONAL
Enrollment 634 participants
Start Date 2026-04-13
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
CommunityRx-Kidney Health

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 634 participants in total. It began in 2026-04-13 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In the United States, the burden of chronic kidney disease (CKD) rests disproportionately on rural communities. This study evaluates the implementation and effectiveness of CommunityRx-Kidney Health (CRx-K); this health information technology intervention integrates medical, social, and self-care resources to improve CKD management in rural eastern North Carolina. Through a partnership among local primary care centers, community organizations, and researchers, CRx-K will strengthen rural care networks, improve CKD management, and enhance the well-being of rural communities.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of chronic kidney disease defined as ≥1 ICD-10 CKD codes (excluding end-stage kidney disease) or CKD biomarkers (estimated glomerular filtration rate ≤ 60 ml/min, albuminuria ≥30 mg/24h) * At least one clinic visit at Goshen Medical Center in 12 months before enrollment Exclusion Criteria: * Limited life expectancy (e.g., advanced cancer, end-stage liver disease, hospice) * Active cancer treatment * Living in a skilled nursing facility * Dementia/other significant cognitive impairment/inability to participate in the informed consent process

Contact & Investigator

Central Contact

Kristen D Witkemper, MPH

✉ CRx-K@med.unc.edu

📞 910-939-1879

Principal Investigator

Gaurav J Dave, MBBS, MPH, DrPH

PRINCIPAL INVESTIGATOR

University of North Carolina, Chapel Hill

Frequently Asked Questions

Who can join the NCT07237295 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease (Stages 1-4). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07237295 currently recruiting?

Yes, NCT07237295 is actively recruiting participants. Contact the research team at CRx-K@med.unc.edu for enrollment information.

Where is the NCT07237295 trial being conducted?

This trial is being conducted at Beulaville, United States.

Who is sponsoring the NCT07237295 clinical trial?

NCT07237295 is sponsored by University of North Carolina, Chapel Hill. The principal investigator is Gaurav J Dave, MBBS, MPH, DrPH at University of North Carolina, Chapel Hill. The trial plans to enroll 634 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology